Sunovion Pharmaceuticals, a US subsidiary of Japanese pharma company Sumitomo Dainippon (TYO: 4506), has signed a definitive agreement to acquire Canadian drugmaker Cynapsus Therapeutics (TSX: CTH) for $40.50 per share in cash.
The transaction has received unanimous approval by the board of directors of both companies and values Cynapsus at around $624 million. The acquisition will be funded with cash on hand and is expected to close in the fourth quarter of 2016. This agreement reflects Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology.
Through this transaction, Sunovion would acquire Cynapsus’ product candidate, APL-130277, which is designed to be a fast-acting, easy-to-use, on-demand treatment option for managing OFF episodes associated with Parkinson’s disease (PD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze